Stock Research for BMYMP

BMYMP

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

BMYMP Stock Chart & Research Data

The BMYMP chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BMYMP chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


BMYMP Due diligence Resources & Stock Charts

The BMYMP stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BMYMP Detailed Price Forecast - CNN Money CNN View BMYMP Detailed Summary - Google Finance
Yahoo View BMYMP Detailed Summary - Yahoo! Finance Zacks View BMYMP Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View BMYMP Trends & Analysis - Trade-Ideas Barrons View BMYMP Major Holders - Barrons
NASDAQ View BMYMP Call Transcripts - NASDAQ Seeking View BMYMP Breaking News & Analysis - Seeking Alpha
Spotlight View BMYMP Annual Report - CompanySpotlight.com OTC Report View BMYMP OTC Short Report - OTCShortReport.com
TradeKing View BMYMP Fundamentals - TradeKing Charts View BMYMP SEC Filings - Bar Chart
WSJ View Historical Prices for BMYMP - The WSJ Morningstar View Performance/Total Return for BMYMP - Morningstar
MarketWatch View the Analyst Estimates for BMYMP - MarketWatch CNBC View the Earnings History for BMYMP - CNBC
StockMarketWatch View the BMYMP Earnings - StockMarketWatch MacroAxis View BMYMP Buy or Sell Recommendations - MacroAxis
Bullish View the BMYMP Bullish Patterns - American Bulls Short Pains View BMYMP Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View BMYMP Stock Mentions - StockTwits PennyStocks View BMYMP Stock Mentions - PennyStockTweets
Twitter View BMYMP Stock Mentions - Twitter Invest Hub View BMYMP Investment Forum News - Investor Hub
Yahoo View BMYMP Stock Mentions - Yahoo! Message Board Seeking Alpha View BMYMP Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for BMYMP - SECform4.com Insider Cow View Insider Transactions for BMYMP - Insider Cow
CNBC View BMYMP Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BMYMP - OTC Markets
Yahoo View Insider Transactions for BMYMP - Yahoo! Finance NASDAQ View Institutional Holdings for BMYMP - NASDAQ


Stock Charts

FinViz View BMYMP Stock Insight & Charts - FinViz.com StockCharts View BMYMP Investment Charts - StockCharts.com
BarChart View BMYMP Stock Overview & Charts - BarChart Trading View View BMYMP User Generated Charts - Trading View




Latest Financial News for BMYMP


How Bristol-Myers Squibb’s Brands Performed in Q2 2018
Posted on Monday August 06, 2018

Due to the jump in its operating expenses, Bristol-Myers Squibb’s net income fell from $916 million in the second quarter of 2017 to $373 million in the second quarter of 2018. Under Bristol-Myers Squibb’s prioritized brands, Opdivo sales increased from $1.19 billion in the second quarter of 2017 to $1.63 billion in the second quarter of 2018 due to its higher demand for the treatment of adjuvant melanoma and liver cancer and its being launched in new countries.


What Analysts Think of Bristol-Myers Squibb
Posted on Monday August 06, 2018

Bristol-Myers Squibb (BMY), which released its second-quarter earnings on July 26, is a global specialty biopharmaceutical company with a focus on developing and commercializing innovative medicines. In the second quarter, Bristol-Myers Squibb delivered a strong performance on the back of higher demand for its prioritized brands, including Opdivo and Eliquis. In August, of the total 20 analysts covering Bristol-Myers Squibb, seven have given the stock “buy” or higher ratings, 11 have given it “hold” ratings, and two have given it “sell” ratings.


Analyzing Bristol-Myers Squibb’s Financial Performance
Posted on Monday August 06, 2018

Bristol-Myers Squibb (BMY) generated total revenue of $5.70 billion in the second quarter compared to $5.14 billion in the second quarter of 2017. Bristol-Myers Squibb’s product sales, which contribute the bulk of its revenue, increased from $4.77 billion in the second quarter of 2017 to $5.46 billion in the second quarter of 2018. For 2018 and 2019, Bristol-Myers Squibb is expected to generate revenues of $22.26 billion and $23.45 billion, respectively.


A Performance Overview of Merck’s Virology and Immunology Drugs
Posted on Monday August 06, 2018

In the second quarter of 2018, Merck’s (MRK) Zepatier generated revenues of $113.0 million compared to $517.0 million in the second quarter of 2017, reflecting a ~78% year-over-year (or YoY) decline and a ~14% decline sequentially. In the first half of 2018, Zepatier generated revenues of $243.0 million, reflecting a ~73% YoY decline.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.